C
CStone Pharmaceuticals
Biopharmaceutical company developing and commercializing oncology and precision medicines
About CStone Pharmaceuticals
CStone Pharmaceuticals (HKEX: 2616) is a Chinese biopharmaceutical company focused on the development and commercialization of innovative oncology and precision medicines. Founded in late 2015 and headquartered in Shanghai, the company builds its portfolio around immuno-oncology assets and precision oncology therapies targeting cancers with high unmet medical need in China and globally.
The company has launched four innovative medicines and secured 21 new drug application approvals covering nine indications. Its marketed products include sugemalimab (CEJEMLY), an anti-PD-L1 antibody approved for non-small cell lung cancer indications, including marketing authorizations in the European Union and the United Kingdom; pralsetinib (GAVRETO), a RET inhibitor; and avapritinib (AYVAKIT), a KIT/PDGFRA inhibitor for gastrointestinal stromal tumors, with China National Reimbursement Drug List inclusions supporting patient access.
CStone's Pipeline 2.0 advances more than nine candidates spanning multispecific antibodies and antibody-drug conjugates, led by CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody in Phase I/II clinical development, and CS5001, an anti-ROR1 antibody-drug conjugate. The company operates an in-house ADC technology platform and a Translational Medicine Research Center in Suzhou. Revenue comes from product sales, licensing and partnership income, with commercialization partnerships extending sugemalimab's reach to more than 60 countries across Europe, the Middle East, North Africa and Latin America.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2019
Open roles
CStone Pharmaceuticals in the Pudong ecosystem
The CStone Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Boyu Capital
WuXi Healthcare Ventures- OCOriza Seed Capital
GIC
Hillhouse Capital
6 Dimensions Capital- KCKing Star Capital
Taikang Life Insurance
Sequoia
CITIC PE
ARCH Venture Partners
YunFeng Capital
Series B and later9 investors entered at this stage
Hillhouse Capital
Sequoia- TITaikang Life Insurance
- KCKing Star Capital
- YCYunFeng Capital
GIC- CPCITIC PE
ARCH Venture Partners- 6C6 Dimensions Capital
Source: Dealroom Talent Intelligence.
Patents
23 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See CStone Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
CStone and Kimia Therapeutics partner to take first-in-class DDR-targeting oncology asset into Phase I in China and Australia
